Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta‐analysis
Authors:
- 28 July 2014
- journal article
- Published by Wiley in Hepatology Research
- Vol. 45 (1) , 48-58
Abstract
The aim of this study was to assess the efficiency and safety of combination therapy of ursodeoxycholic acid (UDCA) and bezafibrate for primary biliary cirrhosis. A meta‐analysis of all long‐term randomized controlled trials comparing the combination of UDCA and bezafibrate with UDCA monotherapy was performed via electronic searches. Seven trials, which included 177 patients, were assessed. Combination therapy with UDCA and bezafibrate was more effective than UDCA monotherapy in improving liver biochemistry, alkaline phosphatase (mean difference [MD], −146.15 IU/L; 95% confidence interval [CI], −193.58 to −98.72; P < 0.00001), γ‐glutamyltransferase (MD, −20.64 IU/L; 95% CI, −30.86 to −10.43; P < 0.0001), immunoglobulin M (MD, −90.96 mg/dL; 95% CI, −137.36 to −44.56; P = 0.0001) and triglycerides (MD, −15.49 mg/dL; 95% CI, −30.25 to −0.74; P = 0.04). However, their effects on pruritus (odds ratio [OR], 0.82; 95% CI, 0.30–2.24; P = 0.70) and alanine aminotransferase (MD, −8.41 IU/L; 95% CI, −22.57 to 5.75; P = 0.24) did not differ significantly. This meta‐analysis revealed no significant differences in the incidence of all‐cause mortality (OR, 0.72; 95% CI, 0.10–5.49; P = 0.75) and adverse events (OR, 0.35; 95% CI, 0.07–1.84; P = 0.22) between patients treated with combination therapy and those treated with monotherapy. In this meta‐analysis, combination therapy with UDCA and bezafibrate was more effective than UDCA monotherapy. Combination therapy improved liver biochemistry, but did not improve clinical symptoms, incidence of death or adverse events more effectively than monotherapy.Keywords
This publication has 28 references indexed in Scilit:
- Effects of Three Different Fibrates on Intrahepatic Cholestasis Experimentally Induced in RatsPPAR Research, 2013
- Protective Effects of Necrostatin-1 against Concanavalin A-Induced Acute Hepatic Injury in MiceMediators of Inflammation, 2013
- Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-AnalysisGastroenterology Research and Practice, 2013
- The Hippo-Yes Association Protein Pathway in Liver CancerGastroenterology Research and Practice, 2013
- Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acidJournal of Gastroenterology and Hepatology, 2011
- Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor α-Independent MechanismMolecular Pharmacology, 2009
- Ursodeoxycholic acid: Mechanism of action and novel clinical applicationsHepatology Research, 2007
- Fibrate for treatment of primary biliary cirrhosisHepatology Research, 2007
- High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver diseaseThe Journal of Pathology, 2003
- Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in miceBiochemical Journal, 2003